Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276)

Market Cap	310.17B
Revenue (ttm)	27.98B
Net Income (ttm)	6.34B
Shares Out	6.36B
EPS (ttm)	1.00
PE Ratio	48.78
Forward PE	45.52
Dividend	0.20 (0.41%)
Ex-Dividend Date	Jul 12, 2024

Volume	22,768,235
Average Volume	65,407,785
Open	48.54
Previous Close	48.90
Day's Range	48.32 - 48.87
52-Week Range	37.24 - 57.53
Beta	0.43
RSI	55.49
Earnings Date	Mar 31, 2025

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; tra...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1970
• Employees: 20,238
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600276

Financial Performance

In 2024, Jiangsu Hengrui Medicine's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.